Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels

Alzheimer's and Dementia

Volumn 10, Issue 5, 2014, Pages S290-S298

  Slaets, Sylvie ^a   Vanmechelen, Eugeen ^b   Le Bastard, Nathalie ^a   Decraemer, Hilde ^b   Vandijck, Manu ^b   Martin, Jean Jacques ^c   De Deyn, Peter Paul ^a,c,d,e   Engelborghs, Sebastiaan ^a,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INNOGENETICS   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Dementia; Dementia with; Lewy bodies tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN 140; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; HEMOGLOBIN; LEVODOPA; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; SNCA PROTEIN, HUMAN;

AGED; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DECISION TREE; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; CEREBROSPINAL FLUID; PATHOLOGY; PHOSPHORYLATION;

AGED; ALGORITHMS; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84908245806     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.10.004     Document Type: Article

References (46)

1. A.R. Merdes, L.A. Hansen, D.V. Jeste, D. Galasko, C.R. Hofstetter, and G.J. Ho Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies Neurology 60 2003 1586 1590
2. N. Le Bastard, J.J. Martin, E. Vanmechelen, H. Vanderstichele, P.P. De Deyn, and S. Engelborghs Added diagnostic value of CSF biomarkers in differential dementia diagnosis Neurobiol Aging 31 2010 1867 1876
3. S. Slaets, Bastard N. Le, J. Theuns, K. Sleegers, A. Verstraeten, and Leenheir E. De Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with Lewy bodies J Alzheimers Dis 35 2013 137 146
4. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
5. T. Tokuda, S.A. Salem, D. Allsop, T. Mizuno, M. Nakagawa, and M.M. Qureshi Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease Biochem Biophys Res Commun 349 2006 162 166
6. B. Mollenhauer, V. Cullen, I. Kahn, B. Krastins, T.F. Outeiro, and I. Pepivani Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Exp Neurol 213 2008 315 325
7. K. Kasuga, T. Tokutake, A. Ishikawa, T. Uchiyama, T. Tokuda, and O. Onodera Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease J Neurol Neurosurg Psychiatry 81 2010 608 610
8. T. Tokuda, M.M. Qureshi, M.T. Ardah, S. Varghese, S.A. Shehab, and T. Kasai Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease Neurology 75 2010 1766 1772
9. B. Mollenhauer, J.J. Locascio, W. Schulz-Schaeffer, F. Sixel-Doring, C. Trenkwalder, and M.G. Schlossmacher alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol 10 2011 230 240
10. Z. Hong, M. Shi, K.A. Chung, J.F. Quinn, E.R. Peskind, and D. Galasko DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease Brain 133 2010 713 726
11. L. Parnetti, D. Chiasserini, G. Bellomo, D. Giannandrea, C.C. De, and M.M. Qureshi Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias Mov Disord 26 2011 1428 1435
12. F. Tateno, R. Sakakibara, T. Kawai, M. Kishi, and T. Murano Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease Alzheimer Dis Assoc Disord 26 2012 213 216
13. M. Noguchi-Shinohara, T. Tokuda, M. Yoshita, T. Kasai, K. Ono, and M. Nakagawa CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease Brain Res 1251 2009 1 6
14. P.E. Spies, R.J. Melis, M.J. Sjogren, M.G. Rikkert, and M.M. Verbeek Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders J Alzheimers Dis 16 2009 363 369
15. F.E. Reesink, A.W. Lemstra, K.D. van Dijk, H.W. Berendse, W.D. van de Berg, and M. Klein CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease J Alzheimers Dis 22 2010 87 95
16. M.B. Aerts, R.A. Esselink, W.F. Abdo, B.R. Bloem, and M.M. Verbeek CSF alpha-synuclein does not differentiate between Parkinson Ian disorders Neurobiol Aging 33 2012 430 433
17. I.G. McKeith, D.W. Dickson, J. Lowe, M. Emre, J.T. O'Brien, and H. Feldman Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 2005 1863 1872
18. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
19. American Psychiatric Association DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders 4th ed. 2000 American Psychiatric Association Washington, DC
20. S. Gilman, G.K. Wenning, P.A. Low, D.J. Brooks, C.J. Mathias, and J.Q. Trojanowski Second consensus statement on the diagnosis of multiple system atrophy Neurology 71 2008 670 676
21. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
22. S. Engelborghs, K. Sleegers, P. Cras, N. Brouwers, S. Serneels, and E. De Leenheir No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease Brain 130 2007 2320 2326
23. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
24. H. Braak, I. Alafuzoff, T. Arzberger, H. Kretzschmar, and T.K. Del Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry Acta Neuropathol 112 2006 389 404
25. S. Engelborghs, K. De Vreese, T. Van de Casteele, H. Vanderstichele, B. Van Everbroeck, and P. Cras Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiol Aging 29 2008 1143 1159
26. S. Hall, A. Ohrfelt, R. Constantinescu, U. Andreasson, Y. Surova, and F. Bostrom Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders Arch Neurol 69 2012 1445 1452
27. A. Ohrfelt, P. Grognet, N. Andreasen, A. Wallin, E. Vanmechelen, and K. Blennow Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450 2009 332 335
28. C.M. Sturgeon, and A. Viljoen Analytical error and interference in immunoassay: minimizing risk Ann Clin Biochem 48 2011 418 432
29. D. Sehlin, S. Sollvander, S. Paulie, R. Brundin, M. Ingelsson, and L. Lannfelt Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs J Alzheimers Dis 21 2010 1295 1301
30. O. Hansson, H. Zetterberg, E. Vanmechelen, H. Vanderstichele, U. Andreasson, and E. Londos Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment Neurobiol Aging 31 2010 357 367
31. K. Beyer, M. Domingo-Sabat, C. Santos, E. Tolosa, I. Ferrer, and A. Ariza The decrease of beta-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies Brain 133 2010 3724 3733
32. H. Rhinn, L. Qiang, T. Yamashita, D. Rhee, A. Zolin, and W. Vanti Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology Nat Commun 3 2012 1084
33. B.I. Giasson, R. Jakes, M. Goedert, J.E. Duda, S. Leight, and J.Q. Trojanowski A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease J Neurosci Res 59 2000 528 533
34. Y. Wang, M. Shi, K.A. Chung, C.P. Zabetian, J.B. Leverenz, and D. Berg Phosphorylated alpha-synuclein in Parkinson's disease Sci Transl Med 4 2012 121ra20
35. J.B. Toledo, A. Korff, L.M. Shaw, J.Q. Trojanowski, and J. Zhang CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease Acta Neuropathol 126 2013 683 697
36. A. Korff, C. Liu, C. Ginghina, M. Shi, and J. Zhang Alpha-synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment J Alzheimers Dis 36 2013 679 688
37. M. Wennstrom, E. Londos, L. Minthon, and H.M. Nielsen Altered CSF orexin and alpha-synuclein levels in dementia patients J Alzheimers Dis 29 2012 125 132
38. W. Thies, and L. Bleiler 2013 Alzheimer's disease facts and figures Alzheimers Dement 9 2013 208 245
39. M. Wennstrom, Y. Surova, S. Hall, C. Nilsson, L. Minthon, and F. Bostrom Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy PLoS One 8 2013 e53250
40. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
41. E. Su, M.J. Bell, S.R. Wisniewski, P.D. Adelson, K.L. Janesko-Feldman, and R. Salonia Alpha-synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia Dev Neurosci 32 2010 385 395
42. H. Wang, K. Wang, W. Xu, C. Wang, W. Qiu, and X. Zhong Cerebrospinal fluid alpha-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase J Neurochem 122 2012 19 23
43. M.E. Larson, M.A. Sherman, S. Greimel, M. Kuskowski, J.A. Schneider, and D.A. Bennett Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology J Neurosci 32 2012 10253 10266
44. P.T. Nelson, G.A. Jicha, R.J. Kryscio, E.L. Abner, F.A. Schmitt, and G. Cooper Low sensitivity in clinical diagnoses of dementia with Lewy bodies J Neurol 257 2010 359 366
45. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and National Institute on Aging Working Group Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group Neurobiol Aging 19 1998 109 116
46. M. Shi, J. Bradner, A.M. Hancock, K.A. Chung, J.F. Quinn, and E.R. Peskind Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression Ann Neurol 69 2011 570 580